<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042545</url>
  </required_header>
  <id_info>
    <org_study_id>PPP001-Ph2-02</org_study_id>
    <nct_id>NCT04042545</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Releif in Patients With Advanced Cancer</brief_title>
  <acronym>PLENITUDE</acronym>
  <official_title>SAFETY AND EFFICACY OF PPP001-kit FOR THE UNCONTROLLED PAIN RELEIF IN PATIENTS WITH ADVANCED CANCER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetra Bio-Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tetra Bio-Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 clinical trial assess the safety and efficacy of inhaled PPP001 to releive the
      pain in 78 advanced cancer patients with uncontrolled symptoms. This is a 4-week treatment
      period study followed by an open label period of 2 years in 6 sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 4-week randomized, double-blind, placebo-controlled, parallel group design trial to
      evaluate the safety and efficacy of inhaled PPP001 on uncontrolled cancer pain in patients
      with symptoms related to advanced incurable cancer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uncontrolled cancer pain will be measured using a patient self rating questionnaire.</measure>
    <time_frame>change from baseline in the EORTC-QLQ-C15-PAL pain multi-item scale score at Week 4.</time_frame>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 Palliative (EORTC-QLQ-C15-PAL). items are rated on a scale of 1 (not at all) to 4 (very much). high scores on a symptom scale correlate to increased symptom burden</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall HRQoL (Health related Quality of Life) of patients with uncontrolled symptoms related to advanced cancer will be measured using a patient self rating questionnaire.</measure>
    <time_frame>change from baseline in the EORTC-QLQ-C15-PAL overall QoL single-item scale score at Week 4</time_frame>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 Palliative (EORTC-QLQ-C15-PAL). single-item scale is rated from 1 (very poor) to 7 (excellent). High scores on a functional scale correspond to better functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The physical, emotional, and total symptom distress will be measured using a patient self rating questionnaire.</measure>
    <time_frame>Change from Baseline in ESAS-r-CS at Weeks 1 and 4</time_frame>
    <description>Revised Edmonton Symptom Assessment System (ESAS-r-CS). 11 core symptoms: pain, tiredness, nausea, depression, anxious, drowsiness, appetite, feeling of well-being, shortness of breath, constipation and trouble sleeping. 11-point NRS ranging from 0 (no symptom) to 10 (worst possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The palliative performance scale will be scored by a healthcare profesional.</measure>
    <time_frame>Change from Baseline in PPS at Weeks 1 and 4</time_frame>
    <description>palliative performance scale version 2 (PPSv2) for measuring functional status in end-of-life patients. A healthcare professional scores each dimension by assigning a value from 100% to 0% (death), with 10% denoting the lowest level of functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The satisfaction of family caregivers of patients with advanced cancer will be measured using a caregiver self rating questionnaire.</measure>
    <time_frame>Change from Baseline in treatment-satisfaction questionnaire at Weeks 1 and 4</time_frame>
    <description>The treatment satisfaction questionnaire (change version) will be used. Scale range is a left to right 7-item scale for caregiver. each item is scored from 5 (Much more satisfied now) to 1 (Much Less satisfied now).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The distress of patients with advanced cancer will be measured using a patient self rating questionnaire</measure>
    <time_frame>Change from Baseline in distress thermometer at Week 4</time_frame>
    <description>distress thermometer adopted as a screening measure to identify and address psychological distress in individuals with cancer. Results support a cut-off score of 3 on the DT to indicate patients with clinically elevated levels of distress .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Cancer Pain</condition>
  <condition>Quality of Life</condition>
  <condition>Pain, Acute</condition>
  <condition>Cannabis Use</condition>
  <arm_group>
    <arm_group_label>inhaled THC/CBD (PPP001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPP001 (pellet with THC/CBD) inhalation with a device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhalation with a device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPP001</intervention_name>
    <description>1 pellet inhaled 3 times a day with a vaporizer device</description>
    <arm_group_label>inhaled THC/CBD (PPP001)</arm_group_label>
    <other_name>QIXLEEF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pellet inhaled 3 times a day with a vaporizer device</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent,

          2. Adult male and female patients at least 18 years of age,

          3. Subject agreed to follow the protocol,

          4. Advanced cancer for which there is no known curative therapy as per investigator's
             judgement,

          5. Patients experiencing at least 2 symptoms related to cancer &gt; 4 on ESAS-r-CS NRS
             including pain symptom,

          6. Life expectancy six weeks or longer with PPS &gt; 50% and PaP Score Group A (30-day
             survival probability &gt;70%),

          7. Negative confusion assessment according to CAM,

          8. The patient is able to perform deep inhalations with FEV1 more than 60%,

          9. Ability to read and respond to questions in English,

         10. A female volunteer must meet one of the following criteria:

             If of childbearing potential - agrees to use one of the accepted contraceptive
             regimens from at least 28 days prior to the first drug administration, during the
             study and for at least 60 days after the last dose, If of non-childbearing potential -
             should be surgically sterile or in a menopausal state,

         11. A male volunteer with sexual partners who are pregnant, possibly pregnant, or who
             could become pregnant must be surgically sterile or agrees to use one of the accepted
             contraceptive regimens from first drug administration until 3 months after the last
             drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Matharan, PhD</last_name>
    <phone>+1(438)8997575</phone>
    <phone_ext>225</phone_ext>
    <email>smatharan@tetrabiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Research Institute</name>
      <address>
        <city>Cave Creek</city>
        <state>Arizona</state>
        <zip>85331</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Suzanne Sisley, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

